Background In this non‐randomized study we aimed to assess the efficacy of the addition of
low molecular weight heparin (LMWH) to gemcitabine (GEM) plus cisplatinum (CDDP) …

Aim: To compare the seropositivity rate of cancer patients with noncancer controls after inactive
SARS-CoV-2 vaccination and evaluate the factors affecting seropositivity. Method: Spike …

The aim of this retrospective, multicenter study was to evaluate clinicopathological characteristics,
prognostic factors and treatment outcomes of teenage and adult patients with high-…

Studies concerning adjuvant systemic therapy and prognosis in male breast carcinoma (MBC)
are limited. We aimed to evaluate outcome of the changing practices of adjuvant systemic …

We have carried out a retrospective analysis of 490 non-Hodgkin’s lymphomas (NHLs),
followed at our clinic, with the purpose of evaluating the clinicopathologic features of these …

It has been suggested that type 2 diabetes mellitus may affect breast cancer prognosis, possibly
due to increased diabetes-related comorbidity, or direct effects of insulin resistance and/…

Background: Medication errors in oncology may cause severe clinical problems due to low
therapeutic indices and high toxicity of chemotherapeutic agents. We aimed to investigate …

The aim of this study was to evaluate prognostic factors, survival rate and the efficacy of the
treatment modalities used in patients with Ewing sarcoma family of tumors (ESFT). Data of …

Lorlatinib is a third-generation tyrosine-kinases inhibitor (TKI) targeting ALK/ROS1 fusions.
The FDA has approved lorlatinib for TKI-pretreated ALK(+) NSCLC, while its approval for …

San Lucas Medical, LLC Page 1 San Lucas Medical, LLC Epidemiology of Colorectal Cancer in
Turkey: A Cross-sectional Disease Registry Study (A Turkish Oncology Group Trial) NF Aykan1 …